跳至主要内容
临床试验/NL-OMON44283
NL-OMON44283已完成不适用

An open label positron emission tomography (PET) imaging study using 89Zirconium to investigate the biodistribution of anti-HER3 monoclonal antibody (mAb) GSK2849330 and characterize its dose receptor occupancy relationship in subjects with advanced HER3-positive solid tumors - study 200980

GlaxoSmithKline0 个研究点目标入组 15 人开始时间: 待定最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
15

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
18 至 99(—)

入选标准

  • Males and females, 18 years and above.
  • Tumors with HER3 expression.
  • No standard therapeutic alternatives.
  • ECOG Performance Status 0-1.
  • Measurable disease suitable for PET imaging.
  • Females of childbearing potential: adequate method of contraception during study.
  • Men must use adequate contraception during study.

排除标准

  • Active central nervous system metastases.
  • Prior HER3- directed treatment.
  • Recent anti-cancer therapy or major surgery.
  • Allergic reaction to previous biological therapy.
  • Prohibited medications during study including immunesuppressants.
  • Significant CV risk, see protocol page 42 for details.
  • Pregnancy or breastfeeding

研究者

相似试验